Over the past ten years, there has been a significant rise in US health care spending, which is currently on pace to reach nearly 20% of GDP by 2023. We believe the recent acceleration of scientific advances and innovation may lower health care costs in the future. Investors recognize these advances could produce big winners, as well as many losers, and are increasingly paying for potential long-term optionality that exists with many biopharmaceutical companies. Rhett Brown, Managing Director and Research Analyst covering the health care sector, provides a detailed overview of health care innovation and how these changes may affect the industry.

Featured Speaker

Rhett E. Brown, CFA

Managing Director, Research Analyst

Rhett Brown is a Managing Director and Research Analyst covering the health care sector. He began working in the investment field in 1996. Prior to joining Lazard in 2005, he was a research analyst covering health care companies at Deutsche Bank Securities and Volpe Brown Whelan & Company. Before entering the investment business, Rhett held various functional roles including basic research, marketing, and sales within the biopharmaceutical industry, working for Amersham Life Science (now GE Healthcare), the Applied Biosystems Division of Perkin Elmer (now owned by Thermo Fisher Scientific), and Immulogic Pharmaceutical Corporation. Rhett has an MBA (Hons) in Finance from the Wharton School, University of Pennsylvania and a BS (Hons) in Biological Sciences from Stanford University.